文献速递肿瘤 PET/CT放射性药物与辐射防护

位点特异性残留化连接子用于18F标记并增强肾脏清除:抗HER2单域抗体片段的应用

Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.
PubMed 文献 · J Nucl Med · 2021-02-26

本研究评估了一种位点特异性18F残留化标记策略,用于抗HER2单域抗体5F7GGC的免疫PET。标记物18F-5F7GGC保持HER2结合亲和力,在BT474M1荷瘤小鼠中肿瘤摄取与iso-125I-SGMIB-5F7相似,但肾脏清除显著更快。小动物PET/CT显示3小时肿瘤高摄取而背景极低。

要点

  • 18F-5F7GGC合成总放射化学产率为8.9%±3.2%,保留HER2结合亲和力与免疫反应性。
  • 小鼠中18F-5F7GGC肿瘤摄取与iso-125I-SGMIB-5F7相似,但肾脏清除显著更快。
  • 小动物PET/CT显示3小时肿瘤高摄取且背景活性极低(除膀胱外)。

核心结论

  • 位点特异性残留化18F标记策略可促进5F7抗HER2单域抗体及其他单域抗体的免疫PET临床转化。

研究设计与样本

  • 将5F7GGC通过硫醇-马来酰亚胺反应位点特异性连接含四嗪的试剂,再通过逆电子需求Diels-Alder环加成与含可被肾刷状缘酶切割连接子和PEG4链的6-18F-氟烟酰基反式环辛烯反应制备18F-5F7GGC。
  • 在HER2表达的BT474M1乳腺癌细胞系和BT474M1皮下异种移植的裸鼠中进行配对标记比较研究,比较18F-5F7GGC与iso-125I-SGMIB-5F7。
  • 在上述小鼠模型中进行18F-5F7GGC给药后的小动物PET/CT成像。

主要发现

  • 18F-5F7GGC的总放射化学产率为8.9%±3.2%,并保持HER2结合亲和力和免疫反应性。
  • 18F-5F7GGC的总细胞相关和细胞内活性与共孵育的iso-125I-SGMIB-5F7相似。
  • 小鼠BT474M1异种移植瘤中18F-5F7GGC的摄取与iso-125I-SGMIB-5F7相似,但18F-5F7GGC从肾脏清除显著更快。
  • 小动物PET/CT成像证实3小时肿瘤高摄取和滞留,除膀胱外背景活性极低。

临床怎么用

  • 该位点特异性残留化18F标记策略有望支持5F7抗HER2单域抗体及其他单域抗体用于免疫PET的临床转化。
  • 18F-5F7GGC在保持肿瘤摄取的同时肾脏清除更快,可能有利于降低肾脏辐射剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-domain antibody fragments (sdAbs) are promising vectors for immuno-PET; however, better methods for labeling sdAbs with 18F are needed. Herein, we evaluate a site-specific strategy using an 18F residualizing motif and the anti-epidermal growth factor receptor 2 (HER2) sdAb 5F7 bearing an engineered C-terminal GGC tail (5F7GGC). Methods: 5F7GGC was site-specifically attached with a tetrazine-bearing agent via thiol-maleimide reaction. The resultant conjugate was labeled with 18F by inverse electron demand Diels-Alder cycloaddition with a trans-cyclooctene attached to 6-18F-fluoronicotinoyl moiety via a renal brush border enzyme-cleavable linker and a PEG4 chain (18F-5F7GGC). For comparisons, 5F7 sdAb was labeled using the prototypical residualizing agent, N-succinimidyl 3-(guanidinomethyl)-5-125I-iodobenzoate (iso-125I-SGMIB). The 2 labeled sdAbs were compared in paired-label studies performed in the HER2-expressing BT474M1 breast carcinoma cell line and athymic mice bearing BT474M1 subcutaneous xenografts. Small-animal PET/CT imaging after administration of 18F-5F7GGC in the above mouse model was also performed. Results:18F-5F7GGC was synthesized in an overall radiochemical yield of 8.9% ± 3.2% with retention of HER2 binding affinity and immunoreactivity. The total cell-associated and intracellular activity for 18F-5F7GGC was similar to that for coincubated iso-125I-SGMIB-5F7. Likewise, the uptake of 18F-5F7GGC in BT474M1 xenografts in mice was similar to that for iso-125I-SGMIB-5F7; however, 18F-5F7GGC exhibited significantly more rapid clearance from the kidney. Small-animal PET/CT imaging confirmed high uptake and retention in the tumor with very little background activity at 3 h except in the bladder. Conclusion: This site-specific and residualizing 18F-labeling strategy could facilitate clinical translation of 5F7 anti-HER2 sdAb as well as other sdAbs for immuno-PET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhou Z, Meshaw R, Zalutsky MR, et al. Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2021. PMID: 33637584. doi:10.2967/jnumed.120.261446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。